Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
5.48
-0.04 (-0.64%)
At close: Apr 28, 2026, 4:00 PM EDT
5.47
0.00 (-0.09%)
After-hours: Apr 28, 2026, 7:45 PM EDT

Decoy Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Revenue
----1.84
Upgrade
Revenue Growth (YoY)
-----64.84%
Upgrade
Cost of Revenue
----8.55
Upgrade
Gross Profit
-----6.71
Upgrade
Selling, General & Admin
3.734.965.727.146.1
Upgrade
Research & Development
0.370.777.1715.84-
Upgrade
Operating Expenses
4.15.7312.8922.986.1
Upgrade
Operating Income
-4.1-5.73-12.89-22.98-12.81
Upgrade
Interest & Investment Income
0.10.160.350.22-
Upgrade
Other Non Operating Income (Expenses)
---0.010.04
Upgrade
EBT Excluding Unusual Items
-4-5.58-12.54-22.74-12.77
Upgrade
Impairment of Goodwill
----8.87-
Upgrade
Pretax Income
-12.52-5.58-12.54-31.61-12.77
Upgrade
Net Income
-12.52-5.58-12.54-31.61-12.77
Upgrade
Net Income to Common
-12.52-5.58-12.54-31.61-12.77
Upgrade
Shares Outstanding (Basic)
00---
Upgrade
Shares Outstanding (Diluted)
00---
Upgrade
Shares Change (YoY)
20.93%----
Upgrade
EPS (Basic)
-129.10-69.54---
Upgrade
EPS (Diluted)
-129.10-69.54---
Upgrade
Free Cash Flow
-4.83-4.53-12.85-17.6-10.2
Upgrade
Free Cash Flow Per Share
-49.78-56.44---
Upgrade
Operating Margin
-----696.27%
Upgrade
Profit Margin
-----693.84%
Upgrade
Free Cash Flow Margin
-----554.29%
Upgrade
EBITDA
-4.09-5.73-12.88-22.97-12.79
Upgrade
D&A For EBITDA
0.0100.010.010.02
Upgrade
EBIT
-4.1-5.73-12.89-22.98-12.81
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.